(lp0
S'Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial ... GlobeNewswire  - Mar 15, 2017 CAMBRIDGE, Mass. and EXTON, Pa., March 15, 2017  -- Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic&nbsp;...Idera Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 17 - Equities.comIdera Pharmaceuticals Inc  Sees Strong Trading Volume After Better-Than ... - BNB Daily '
p1
aS"Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially ... Seeking Alpha - Feb 27, 2017 Idera Pharmaceuticals  is a clinical-stage biopharmaceutical company developing novel nucleic acid based therapies for the treatment of certain cancers and rare diseases.Shares of Idera Pharmaceuticals, Inc.  Plunge -4.02% - Energy IndexVolatility Analysis: Idera Pharmaceuticals, Inc.  - The Oracle Examiner"
p2
aS"How Much Potential Does Idera Pharmaceuticals' Pipeline Really Have? Motley Fool - Oct 9, 2016 However, Idera isn't the only company developing a potential treatment for the disease. Corbus Pharmaceuticals  expects to complete enrollment in the first half of 2017 for its phase 2 study of Resunab in treating dermatomyositis. Resunab&nbsp;..."
p3
aS'Why Idera Pharmaceuticals Inc Stock Is Falling Again Motley Fool - Oct 7, 2016 Investors in Idera Pharmaceuticals  are having another rough day. Shares are down by more than 10% as of 11:45 a.m.'
p4
aS'Why Idera Pharmaceuticals Inc. Is Down Big Today Motley Fool - Oct 6, 2016 Idera produced a net loss of $26.3 million through the first half of the year, leaving it with only $64.1 million in cash as of the end of June.Idera Pharmaceuticals Sinks on Secondary Offering - 24/7 Wall St.Idera Announces $50M Public Offering  - Investopedia'
p5
aS'Idera Pharmaceuticals Inc  Reports Additional Phase 1/2 Data In ... Smarter Analyst - Feb 24, 2017 Idera Pharmaceuticals Inc  is reporting additional data from the dose-escalation phase of its ongoing Phase 1/2 clinical trial of intratumoral IMO-2125, an agonist of TLR9 in combination with ipilimumab or pembrolizumab for treatment of&nbsp;...Analyst Activity  Wedbush Reiterates Outperform on Idera Pharmaceuticals ... - Market Exclusive'
p6
aS'Idera Pharmaceuticals: An Intriguing Biotech Buy With Near-Term Catalysts Seeking Alpha - Oct 14, 2016 The company is currently exploring strategic options with former lead treatment IMO-8400, opting instead to focus resources on its immuno-oncology candidate, IMO-2125.'
p7
aS'Stock Update : Idera Pharmaceuticals Inc Announces Appointment of ... Smarter Analyst - Feb 6, 2017 Idera Pharmaceuticals Inc  announced the appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development.Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice ... - GlobeNewswire '
p8
aS'Idera Pharmaceuticals  Looks Good: Stock Up 13.3% Yahoo Finance - Mar 1, 2017 Idera Pharmaceuticals, Inc. IDRA was a big mover last session, as the company saw its shares rise over 13% on the day.'
p9
aS'Idera Pharmaceuticals Inc : Here Are The Catalysts To Watch Insider Financial - Feb 7, 2017 Idera Pharmaceuticals Inc  is one of those stocks that starts off looking incredibly promising, and then over time struggles to maintain investor interest in its operations, and as a result, gradually declines in line with the ebbing of ...Idera Pharmaceuticals, Inc.  expected to move 3% in response to ... - Post AnalystIdera Pharmaceuticals, Inc.  Approaching Earnings Date: What ... - The Voice Registrar'
p10
a.